Is Amivantamab covered by medical insurance?

Amivantamab (Amivantamab) is an emerging biologic drug designed to treat a specific type of non-small cell lung cancer (NSCLC). It represents an innovation in the field of immunotherapy with a unique mechanism of action, making it highly anticipated in cancer treatment.

Evantuzumab is not currently on the market in China, and therefore cannot be included in medical insurance. Therefore, patients cannot purchase it domestically and need to purchase evantuzumab through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.

The mechanism of action of evantumumab is one of its outstanding features. It is a bispecific antibody that simultaneously binds to two different molecular targets: epidermal growth factor receptor (EGFR) and tumor neoantigenMET. By binding to these two receptors, evantumumab can simultaneously interfere with the growth signals of tumor cells, thereby slowing or inhibiting the proliferation and spread of cancer cells.

The main indication is the treatment of EGFR Exon 20insertion mutation (EGFR Exon 20 Insertion Mutation)-positive advanced NSCLC patients. This mutation is a relatively rare but difficult-to-treat subtype of NSCLC that is often insensitive to traditional EGFR-inhibiting drugs. Therefore, evantumumab fills a gap in this therapeutic need and provides a new treatment option for these patients.

Evantumumabhas demonstrated excellent antitumor activity in clinical trials, particularly in patients who had previously received other treatments with limited efficacy. It is expected to significantly extend progression-free survival and improve patient survival rates, bringing new treatment hope to this rare subtype of lung cancer.